Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Historical Holders from Q1 2023 to Q3 2025

Symbol
IKT on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
78,158,525
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
54,964,771
Holdings value
$89,043,214
% of all portfolios
0%
Number of holders
53
Number of buys
22
Number of sells
-17
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sands Capital Life Sciences Pulse Fund II, L.P. 14.7% $20,257,500 10,950,000 Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2025
ADAR1 Capital Management, LLC 9.9% -0.9% $14,314,734 +$1,375,379 7,737,694 +11% ADAR1 Capital Management GP, LLC 30 Jun 2025
Fairmount Funds Management LLC 9.9% $15,861,980 7,018,575 Fairmount Funds Management LLC 31 Dec 2024
Nantahala Capital Management, LLC 7.54% $11,974,890 5,298,624 Nantahala Capital Management, LLC 31 Dec 2024
ARMISTICE CAPITAL, LLC 4.99% $7,975,554 3,529,006 Armistice Capital, LLC 31 Dec 2024

Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 54,964,771 $89,043,214 +$712,913 $1.62 53
2025 Q2 54,512,097 $106,299,597 +$5,482,917 $1.95 48
2025 Q1 51,462,756 $112,702,942 +$3,027,389 $2.19 47
2024 Q4 50,059,308 $162,691,896 +$161,164,562 $3.25 31
2024 Q3 860,232 $1,118,330 +$30,199 $1.3 11
2024 Q2 836,496 $1,021,038 +$723,392 $1.21 12
2024 Q1 205,558 $443,782 -$62,190 $2.16 12
2023 Q4 235,004 $298,925 -$271,105 $1.27 11
2023 Q3 429,662 $597,627 -$496,803 $1.39 13
2023 Q2 747,138 $2,693,647 +$2,394,678 $3.61 14
2023 Q1 82,817 $54,460 +$54,460 $0.6576 1